PTC Therapeutics (NASDAQ:PTCT) Director Sells $1,088,787.00 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Emma Reeve sold 15,666 shares of the company’s stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $69.50, for a total transaction of $1,088,787.00. Following the transaction, the director owned 6,666 shares of the company’s stock, valued at approximately $463,287. This represents a 70.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Emma Reeve also recently made the following trade(s):

• On Friday, October 3rd, Emma Reeve sold 25,562 shares of PTC Therapeutics stock. The stock was sold at an average price of $65.96, for a total transaction of $1,686,069.52.
• On Thursday, September 11th, Emma Reeve sold 15,705 shares of PTC Therapeutics stock. The stock was sold at an average price of $59.50, for a total transaction of $934,447.50.

PTC Therapeutics Stock Up 0.3%

PTCT stock opened at $68.31 on Monday. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $69.88. The company has a fifty day simple moving average of $61.23 and a two-hundred day simple moving average of $52.88. The firm has a market capitalization of $5.43 billion, a P/E ratio of 9.80 and a beta of 0.55.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.24. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The business had revenue of $178.88 million during the quarter, compared to analyst estimates of $173.01 million. During the same quarter last year, the business earned ($1.29) earnings per share. PTC Therapeutics’s quarterly revenue was down 4.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS. As a group, analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on PTCT. Cantor Fitzgerald reiterated an “overweight” rating and set a $118.00 price objective on shares of PTC Therapeutics in a research report on Wednesday, September 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of PTC Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada reiterated an “outperform” rating and set a $63.00 price objective (up previously from $60.00) on shares of PTC Therapeutics in a research report on Friday, August 8th. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research report on Friday, August 8th. Finally, Bank of America lowered their price objective on shares of PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating for the company in a research report on Wednesday, August 20th. Ten investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $69.57.

Institutional Investors Weigh In On PTC Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in PTCT. GAMMA Investing LLC raised its stake in shares of PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 441 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of PTC Therapeutics in the first quarter valued at $595,000. Allspring Global Investments Holdings LLC purchased a new position in PTC Therapeutics in the 1st quarter worth about $524,000. GF Fund Management CO. LTD. increased its stake in PTC Therapeutics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,974 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 355 shares during the period. Finally, Banque Pictet & Cie SA purchased a new position in PTC Therapeutics in the 1st quarter worth about $342,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.